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Abstract There is growing evidence for the role of protein 
tyrosine phosphatases in controlling such fundamental cellular 
processes as growth and differentiation. Pervanadate is a potent 
inhibitor of protein tyrosine phosphatase which has been observed 
here to induce proliferation in C3H10T1/2 mouse fibroblasts. 
Pervanadate also translocated/activated p42/44 mitogen-acti-
vated protein (MAP) kinase to the cell nucleus. An almost 
similar pattern of nuclear p42/44 MAP kinase stimulation is seen 
with TPA. On the other hand, TPA treatment results in a rapid 
activation of cytosolic M A P kinase which declines with time. 
Thus pervanadate appears as a very useful tool for studying 
tyrosine phosphorylation. 
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1. Introduction 
It is now well established [1,2] that some of the events 
occurring during proliferation are regulated by coordinate ac-
tions of protein tyrosine kinases and protein tyrosine phos-
phatases. One of the major signalling systems by which cells 
sense extracellular responses and transmit them intracellularly 
concerns the mitogen-activated protein kinase (MAPK) path-
ways [3-5]. Four subgroups of M A P K s have been identified: 
the E R K s (extracellular signal-regulated kinases) [6], Jun ki-
nases [7], p38 M A P kinases [8], and B M K l / E r k - 5 [9]. While 
E R K s are mainly activated by mitogenic signals, the J N K and 
p38 subclass of M A P K s are regulated as a sensor for stress 
signals [10]. The M A P K s are stimulated by dual phosphoryl-
ation [11] on threonine and tyrosine by upstream M A P K 
kinase (MAPKK) . Thus one way by which growth stimuli 
transduce their growth promoting or proliferating signal is 
the activation of tyrosine kinases. On the other hand, inhi-
bition [12-15] of tyrosine phosphatases has been shown to 
mimic some of the aspects of signal transduction that are 
normally triggered by tyrosine kinase activation pathway. Per-
vanadate has been reported to be a potent inhibitor of tyro-
sine phosphatase and thereby activates M A P kinase pathway 
[16]. In the study reported here we document that treatment 
of C3H10T1/2 mouse fibroblasts in culture with pervanadate 
leads to a proliferative response monitored by enhanced D N A 
synthesis and increased cell numbers. We also document that 
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pervanadate treatment of fibroblasts translocates/activates 
M A P kinase to the cell nucleus. 
2. Materials and methods 
2.1. Materials 
C3H10T1/2 embryonic mouse fibroblasts were obtained from Dr. 
C.E. Wenner (Buffalo, NY). [y-32P]ATP and 5-[125I]iodo-2'-deoxy-
uridine were purchased from Amersham, antiphosphotyrosine anti-
body was from Transduction Laboratory, anti-ERK-2 antibody was 
from Santa Cruz Biotechnology, and all other reagents of highest 
purity grade were from Sigma France. Pervanadate (phosphotyrosine 
phosphatase inhibitor) was prepared as described by Zhao et al. [16]. 
2.2. Cell cultures 
C3H10T1/2 embryonic mouse fibroblasts [17] were used at passage 
15-22 at post-confluence quiescent state. Cultures were maintained in 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 
10% inactivated fetal calf serum in a 5% CO2 atmosphere at 37°C. 
The culture medium was renewed 5 days after plating on Petri dishes 
and cells attained confluence 9-10 days. Post-confluent cells were sub-
jected to serum starvation for 48 h followed by treatment with TPA or 
pervanadate. 
2.3. Preparation of cytosol and nuclear fractions 
The cells were harvested in a medium containing 20 mM HEPES, 
2 mM EDTA and 10% glycerol, sonicated 2 times (5 s each) with a 
1 min interval between two sonications and centrifuged at lOOOOOXg. 
The resulting supernatant constituted the cytosolic fraction. Post-con-
fluence cells were deprived of serum for indicated period. Cells were 
treated with TPA or pervanadate as required. Following treatments, 
cells were rinsed gently 3 times with a medium containing 20 mM 
Tris-HCl, pH 7.5, 1 mM MgCl2, and 1 mM dithiothreitol (medium 
A). Petri dishes, with attached cells, were frozen at —80°C for 2 h 
having a minimum amount of the above medium. After thawing on 
ice, cells were harvested in the medium A, centrifuged at 600 Xg for 
10 min at 4°C and the resulting pellet was homogenized in 2 vol. of 
medium A supplemented with 1.3 M sucrose. Adequate amounts of 
medium A supplementing with 2.4 M sucrose were added to this 
suspension so as to give a final concentration of 2.2 M sucrose in 
the medium. This was homogenized with 4 up and down strokes in 
a Dounce homogenizer and centrifuged at lOOOOOXg for 20 min at 
4°C in a Beckman TL 100 ultracentrifuge. The resulting pellet con-
stituted isolated nuclei which were devoid of any plasma membrane 
contaminants as attested by marker enzymes activity [18]. The isolated 
nuclei were resuspended in a medium containing 20 mM Tris-HCl, pH 
7.5, 4 mM MgCl2, 2 mM EDTA, 10% glycerol, 0.5% Triton X-100, 
2 mM phenylmethylsulfonyl fluoride, 2 mM Na3VO,i, 20 mM NaF, 
10 M,g/ml leupeptine and aprotonine, 25 ug/ml trypsin inhibitor and 
sonicated 3 times. This was centrifuged at lOOOOOXg for 20 min at 
4°C the supernatant constituted the nuclear fraction. 
2.4. MAP kinase activity 
The standard assay medium contained: 20 mM HEPES, pH 7.5, 
20 mM P-glycerophosphate, pH 7.5, 20 mM NaF, 2 mM EDTA, 
2 mM Na3V04 , 10 mM MgCl2, 100 uM ATP, 0.28 mg/ml myelin 
basic protein (MBP) and 3-5 XlO5 cpm [y!2-P]ATP. Appropriate 
amounts of MAP kinase containing fraction (cytosolic/nuclear) was 
incubated for 15 min at 30°C. After incubation, proteins were pre-
cipitated with 20% TCA and radioactivity was determined by Ceren-
kow spectrometry. 
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2.4.1. Western blotting 
Fractions endowed with MAP kinase activity were mixed with elec-
trophoresis sample buffer and boiled for 5 min at 90°C. Proteins were 
separated on SDS-PAGE (10% polyacrylamide). After electrophoresis 
proteins were transferred to nitrocellulose membranes using BioRad 
semi-dry apparatus. The immunoblot was revealed using an anti-
ERK-2 antibody (1:1000 dilution), or antiphosphotyrosine antibody 
(1:250 dilution) as primary antibody employing alkaline phosphatase-
conjugated secondary antibody. The immunoblot was developed using 
NBT-BCIP reagent. 
2.5. DNA synthesis 
For 125I-labelled uridine incorporation assay, cells were plated in 
24-well plates (Falcon, Oxnard, CA) at a density of 1.6 X 106 cells per 
well. Cells were deprived of serum for 48 h followed by various treat-
ments. For instance cells were treated with 10% fetal calf serum, 
160 nM TPA (without serum for 10 min) 12.5 uM freshly prepared 
pervanadate (with 10% serum for 2 h). Cells were pulsed labelled with 
1.2 XlO5 cpm of iodinated uridine for 2 h. Cells were centrifuged at 
600 Xg for 10 min and radioactivity was determined by spectrometry 
counting. 
2.5.1. Cell counting 
Cells were plated in 30 mm Petri dishes at a density of 1.25XlO5 
cells per dish and allowed to grow. Cells were serum-deprived for 48 h, 
followed by effector treatment as mentioned above. Cells were rinsed 
extensively and counted after Trypan Blue staining. 
3. Results 
3.1. Pervanadate-induced proliferation 
Fig. 1A illustrates enhanced DNA synthesis as monitored 
by [125I]iodo-2'-deoxyrudine incorporation upon effector 
treatment. Pervanadate caused maximum uridine incorpora-
tion as compared with TPA treatment or treatment with fetal 
calf serum. The uridine incorporation was dependent upon the 
time employed to continue cell growth after an initial short-
term effector treatment, with maximum uridine incorporation 
occurring at 15 h. 
Both pervanadate or TPA treatment of fibroblasts resulted 
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Fig. 1. Pervanadate-induced proliferation. Mouse fibroblasts were treated with pervanadate (•), serum (o), phorbol ester ( A ) as described 
under Section 2. Enhanced DNA synthesis was determined by 125I-labelled deoxyuridine incorporation (A) and cells were counted after Trypan 
Blue staining (B). Concentrations of effectors were: pervanadate, 12.5 uM; phorbol ester, 160 nM; serum 10%. 
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Fig. 2. p42/44 MAP kinase activity. MAP kinase activity was determined in the cytosolic (o) and nuclear fractions (•) derived from pervana-
date (A) or TPA (B) treated cells as described under Section 2. Standard assay medium contained in (mM): 20 HEPES, pH 7.5; 20 P-glycero-
phosphate, pH 7.5; 20 NaF; 2 EDTA; 2 Na3V04; 10 MgCl2; 100 uM ATP, 3-5 XlO
5 cpm [y-32P]ATP and 0.28 mg/ml MBP. The incubation 
was carried out at 30°C for 15 min. 
in increased cell numbers (Fig. IB) which further confirmed 
the proliferative response of these effectors in C3H10T1/2 fi-
broblasts. 
3.2. Pervanadate stimulates and translocates MAP kinase to 
the nucleus 
C3H10T1/2 mouse fibroblasts were treated with pervana-
date (Fig. 2A) and TPA (Fig. 2B) and MAP kinase activity 
was determined in the cell cytosol and the cell nucleus. Perva-
nadate treatment resulted in sustained activation of MAP ki-
nase in the cytosolic and nuclear fractions. The activities 
reached plateau level within 10 min of cell treatment and 
stayed thereafter. The TPA treatment stimulated MAP kinase 
activity in the cytosolic fraction within 5 min, which declined 
from then on, attaining to a lower level in 30 min. The nuclear 
MAP kinase activity showed a biphasic response (Fig. 2B). 
There was a tendency for a transient stimulation which ap-
peared to follow a slow rise in activity attaining maximum 
stimulation in 30 min. A similar pattern of nuclear MAP 
kinase stimulation was seen either with pervanadate or TPA 
treatment of cells. 
Activation of MAP kinase was also supported by Western 
blot data obtained employing anti-ERK-2 antibody as well as 
antiphosphotyrosine antibody. A time-dependent activation of 
MAP kinase was seen upon pervanadate treatment in the 
cytosol (Fig. 3A,B) and in the nucleus (Fig. 3C,D). Slow mo-
bility of ERK-2 on electrophoresis due to stimulation of MAP 
kinase within the time frame of enhanced activity found full 
confirmation from the antiphosphotyrosine immunoblotting 
(Fig. 3B,D) results. 
4. Discussion 
Activation of protein tyrosine kinases is a critical compo-
nent of signalling pathways that control cell proliferation and 
differentiation. The importance of protein tyrosine phospha-
tase in the regulation of cell function has recently been em-
phasized [1,19,20]. Most interesting results were advanced by 
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Fischer demonstrating that inactivation of protein tyrosine 
phosphatases by pervanadate produced drastic tyrosine phos-
phorylation of cellular proteins, which ultimately turn on the 
MAP kinase pathway [16]. Furthermore, Cohen [20] has come 
up with the still striking observation when he and his col-
leagues observed tyrosine phosphorylation of a number of 
proteins, as well as nuclear translocation of a number of ty-
rosine phosphorylated stat (signal transducer and activator of 
transcription) proteins, upon intraperitoneal injection of per-
vanadate into mice. Thus, Cohen [20] has established that the 
control of protein tyrosine phosphatase activity may be of 
greater significance in cell signaling than heretofore realized. 
However, the role of pervanadate in inhibiting protein tyro-
sine phosphatase with respect to cell proliferation has not 
been addressed adequately. 
The present study demonstrates that pervanadate can serve 
as an inducer of cell proliferation in C3H10T1/2 mouse fibro-
blasts in culture. The effect of pervanadate on cell prolifera-
tion was comparable with that of TPA or serum. DNA syn-
thesis was enhanced (Fig. 1A), and cell numbers were 
increased (Fig. IB). Therefore, inactivation of protein tyrosine 
phosphatase leads to a proliferative response in this cell sys-
tem. These results establish for the first time that pervanadate 
is a potent inducer of mouse fibroblasts proliferation. They 
confirm that a balance between protein tyrosine phosphatases 
and tyrosine kinase activity [21,22] is essential for the regula-
tion of cell proliferation. 
Another important message that is conveyed by the data 
reported in this article is that treatment of mouse fibroblasts 
in culture by pervanadate leads to nuclear activation and 
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Fig. 3. Western blotting after pervanadate treatment. Cytosolic 
(A,B) or nuclear (C,D) fractions were separated on SDS-PAGE and 
transferred to nitrocellulose membranes. The nitrocellulose mem-
branes were subjected to Western blotting employing anti-ERK anti-
bodies (A,C) or anti-phosphotyrosine antibodies (B,D). Lane 1: 
control; lanes 2-5 pervanadate treatment for 5, 10, 30 and 60 min, 
respectively. Antiphosphotyrosine antibody recognized the ERK-2 
only when the enzyme was activated. For Western blotting in A 
and C, 8 ug protein was loaded in each lane; in B and D, 16 ug 
protein was loaded. 
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Fig. 4. Western blotting after TPA treatment. A,C: Western blots 
obtained using anti-ERK antibodies. B,D: Followed by anti-phos-
photyrosine antibodies. Experimental conditions, amount of protein 
loaded to each lane and time of treatment corresponding to each 
lane were the same as described for Fig. 3. 
translocation of p42/44 MAP kinase (Fig. 2A,B). A similar 
profile was observed for TPA stimulation of nuclear MAP 
kinase activity. However, the pattern of cytosolic p42/44 ki-
nase activation by pervanadate is at variance with that in-
duced by TPA stimulation. Pervanadate induced MAP kinase 
activation was sustained up to 60 min both in the cytosol and 
in the nuclear fraction. On the other hand, in the cytosol 
MAP kinase activation by TPA was maximum 5 min after 
treatment and declined progressively thereafter. 
These results are compatible with the stimulation/transloca-
tion of MAP kinase to the nucleus [23,24] both by TPA and 
pervanadate. However, in the case of TPA stimulation, the 
phosphatases [25,26] which physiologically inactive MAP ki-
nase in the cytosol are not inhibited. Thus, as observed here, 
the activity of MAP kinase in the cytosol would be expected 
to decline. Several dual specificity phosphatases which inacti-
vate MAP kinase have been identified and so far they have 
not been found in the nucleus. It may be safely argued here 
that in the presence of pervanadate, as these phosphatases are 
inhibited, the cytosolic activity of MAP kinase ought to be 
sustained. This is precisely what we have observed. 
The activation of p42/44 MAP kinase was fully supported 
by and immunoreactivity with antiphosphotyrosine antibody, 
and the gel mobility shift (Figs. 3 and 4). The antiphospho-
tyrosine antibody which recognized only the activated p42/44 
MAP kinase, confirmed that a time-dependent activation of 
MAP kinase occurred upon pervanadate treatment of mouse 
fibroblasts in culture. The time course of MAP kinase phos-
phorylation on tyrosine residues was the same as that of MAP 
kinase activity. This parallelism holds for both pervanadate 
and TPA stimulation, except that the intensity of immuno-
reactivity which was much more pronounced after pervana-
date treatment of cells. These results are further evidence [16] 
showing that pervanadate is a potent activator of MAP kinase 
through inhibition of protein tyrosine phosphatase. 
In conclusion, pervanadate is able to induce cell prolifera-
tion and activate MAP kinase in the nucleus. These results 
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further strengthen the role of protein tyrosine phosphatase in 
nuclear signalling and cell proliferation. 
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